Eligibility, any sex, with Cardiovascular Disease or Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)Primary· Baseline
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point \[combination of administrative med data pull and self-report at assessment\]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Group
Value
95% CI
Pharmacist CVD
32.4
± 18.8
Education Control
31.6
± 18.6
Mean Systolic Blood PressureSecondary· Baseline
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
130.6
± 18.5
Education Control
129.7
± 18.8
Mean Systolic Blood PressureSecondary· 6 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
128.3
± 16.5
Education Control
127.7
± 16.8
Mean Systolic Blood PressureSecondary· 12 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
128.5
± 15.4
Education Control
126.4
± 16.2
Mean Diastolic Blood PressureSecondary· Baseline
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
75.8
± 11.5
Education Control
75.8
± 12.4
Mean Diastolic Blood PressureSecondary· 6 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
74.0
± 11.0
Education Control
74.1
± 11.9
Mean Diastolic Blood PressureSecondary· 12 months
Mean BP is calculated as the average of 3 bp measurements. Collected during BP outcome measurement conducted at interviews
Group
Value
95% CI
Pharmacist CVD
73.4
± 10.3
Education Control
73.1
± 10.9
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)Primary· 6 months
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point \[combination of administrative med data pull and self-report at assessment\]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Group
Value
95% CI
Pharmacist CVD
30.0
± 17.2
Education Control
30.2
± 18.7
Framingham Risk Percent (Estimate of 10 Year Risk of Cardiovascular Disease in Percent)Primary· 12 months
Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point \[combination of administrative med data pull and self-report at assessment\]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and CPRS data review). "New cases" of diabetes are allowed to be updated at 6 and 12 months f/u.
Group
Value
95% CI
Pharmacist CVD
28.9
± 15.5
Education Control
28.4
± 18.3
Medication Non-adherenceSecondary· Baseline
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Group
Value
95% CI
Pharmacist CVD
137
Education Control
110
Medication Non-adherenceSecondary· 6 months
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Group
Value
95% CI
Pharmacist CVD
92
Education Control
85
Medication Non-adherenceSecondary· 12 months
First 4 items of the 5 item Morisky Self-reported measure of medication adherence was used to determine medication non-adherence.
Group
Value
95% CI
Pharmacist CVD
96
Education Control
82
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse events were collected through out the study from baseline thru completion..
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have \> 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07497932 — Nutritional Effects in Cardiovascular Surgery
· NA
· recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients
· Phase 4
· recruiting
NCT06485700 — Peers and Technology for Adherence, Access, Accountability, and Analytics (PT4A)
· NA
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 27 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01142908.